



Great Basin Announces Reverse Stock Split of Common Stock

Salt Lake City, December 11, 2015 - Great Basin Scientific, Inc. (NASDAQ: GBSN), a molecular diagnostics company, announced today that a 1-for-60 reverse split of its common stock will be effective at 5:00 pm EST on December 11, 2015. The Company's common stock will open for trading on the Nasdaq Capital Market on Monday, December 14, 2015 on a post-split basis. At the effective time of the reverse stock split, every 60 shares of the Company's issued and outstanding common stock, par value \$0.001, will be consolidated into 1 newly issued and outstanding share of common stock, par value of \$0.0001.

The reverse stock split will reduce the number of shares of the Company's outstanding common stock from approximately 190.7 million to approximately 3.2 million. Proportional adjustments will be made to the Company's outstanding preferred shares, unit purchase options, stock options, warrants, and equity incentive plan. The number of authorized shares of the Company's common stock will remain unchanged.

Effectiveness of the reverse stock split will also cure the Company's previously announced Authorized Share Failure and at that time the Series C Warrants will become exercisable for the next 25 trading days as previously announced on December 7, 2015.

Stockholders who have existing stock certificates will receive written instructions by mail from the Company's transfer agent, American Stock Transfer & Trust Company, LLC. Stockholders who hold their shares in brokerage accounts or "street name" are not required to take any action to effect the exchange of their shares. Such stockholders will be contacted by their brokers with instructions. To the extent the reverse stock split would result in a stockholder owing a fractional share, such stockholder will have the number of post-reverse split shares to which they are entitled rounded up to the next whole number of shares. No stockholders will receive cash in lieu of fractional shares.

Additional information regarding the Company's reverse stock split is available in the definitive proxy statement filed by the Company with the U.S. Securities and Exchange Commission (SEC) on November 3, 2015.



About Great Basin Scientific

Great Basin Scientific is a molecular diagnostics company that commercializes breakthrough chip-based technologies. The Company is dedicated to the development of simple, yet powerful, sample-to-result technology and products that provide fast, multiple-pathogen diagnoses of infectious diseases. The Company's vision is to make molecular diagnostic testing so simple and cost-effective that every patient will be tested for every serious infection, reducing misdiagnoses and significantly limiting the spread of infectious disease.

Forward-Looking Statements

This press release includes forward-looking statement regarding events, trends and business prospects, which may affect our future operating results and financial position, including statements regarding the effective date of the reverse stock split. Forward-looking statements involve risk and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risk and uncertainties include, but are not limited to: (i) our limited operating history and history or losses; (ii) our ability to develop and commercialize new products and the timing of commercialization; (iii) our ability to obtain capital when needed; and (iv) other risks set forth in the Company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof and Great Basin Scientific specifically disclaims any obligation to update these forward-looking statements, except as required by law.

Media Contact:

Kate Ottavio Kent
ICR
203.682.8276
Kate.Ottavio-Kent@icrinc.com

Investor Relations Contact:

David Clair
ICR
646.277.1266
David.Clair@icrinc.com